Combination treatment for advanced solid tumors
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of three drugs (tislelizumab, bevacizumab, and capecitabine) for people with advanced solid tumors, including some who have not responded to immunotherapy or have brain metastases. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older.
- You have advanced or metastatic cancer that has spread or cannot be removed, and you have already had at least one standard treatment (or cannot have it).
- You are able to take care of yourself (fully active or up and about, but not bedridden).
- Your cancer can be measured or seen on scans.
- Your organs (blood counts, liver, kidneys) are working well enough, and your blood pressure is controlled.
- You do not have serious heart, bleeding, or other medical conditions that make study drugs unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.